Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target

• Published in: BMC genomics 2024-02, Vol.25 (1), p.183-183, Article 183
• Main Authors: Li, Wei, Huang, Limei, Qi, Nana, Zhang, Qinle, Qin, Zailong
• Format: Article
• Language: English
• Subjects: Biomarkers; Breast cancer; CALD1; Cancer; Cancer therapies; Chemoresistance; Chemotherapy; Cisplatin; Colon; CYR61 protein; Cytoskeleton; Data analysis; Datasets; Diagnostic systems; Drug resistance; Drug therapy; Encyclopedias; FDA approval; Gene expression; Genes; Genetic aspects; Genomes; Immunotherapy; Malignancy; Medical prognosis; Metastases; Molecular weight; Mutation; Oncology, Experimental; Ovarian cancer; Patients; Platinum; Platinum resistance; Plotters; Prognosis; Prognosis value; Prostate; Protein expression; Proteins; Survival; Target; Tumors
• ISSN: 1471-2164; 1471-2164
• DOI: 10.1186/s12864-024-10056-0

Ovarian cancer (OC) has the worst prognosis among gynecological malignancies, most of which are found to be in advanced stage. Cell reduction surgery based on platinum-based chemotherapy is the current standard of treatment for OC, but patients are prone to relapse and develop drug resistance. The objective of this study was to identify a specific molecular target responsible for platinum chemotherapy resistance in OC. We screened the protein-coding gene Caldesmon (CALD1), expressed in cisplatin-resistant OC cells in vitro. The prognostic value of CALD1 was evaluated using survival curve analysis in OC patients treated with platinum therapy. The diagnostic value of CALD1 was verified by drawing a Receiver Operating Characteristic (ROC) curve using clinical samples from OC patients. This study analyzed data from various databases including Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), The Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA), GEPIA 2, UALCAN, Kaplan-Meier (KM) plotter, LinkedOmics database, and String. Different expression genes (DEGs) between cisplatin-sensitive and cisplatin-resistant cells were acquired respectively from 5 different datasets of GEO. CALD1 was selected as a common gene from 5 groups DEGs. Online data analysis of HPA and CCLE showed that CALD1 was highly expressed in both normal ovarian tissue and OC. In TCGA database, high expression of CALD1 was associated with disease stage and venous invasion in OC. Patients with high CALD1 expression levels had a worse prognosis under platinum drug intervention, according to Kaplan-Meier (KM) plotter analysis. Analysis of clinical sample data from GEO showed that CALD1 had superior diagnostic value in distinguishing patients with platinum "resistant" and platinum "sensitive" (AUC = 0.816), as well as patients with worse progression-free survival (AUC = 0.741), and those with primary and omental metastases (AUC = 0.811) in ovarian tumor. At last, CYR61 was identified as a potential predictive molecule that may play an important role alongside CALD1 in the development of platinum resistance in OC. CALD1, as a member of cytoskeletal protein, was associated with poor prognosis of platinum resistance in OC, and could be used as a target protein for mechanism study of platinum resistance in OC.